

SESSIONS

PRE-EVENT ACTIVITIES (APRIL 23, 2024) - 23/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Welcome Reception

17:30 - 19:30

Date: Tuesday, April 23 2024

Time: 17:30 - 19:30 SGT

Location:

Kinki Restaurant and Bar

70 Collyer Quay

#02-02 Customs House

Singapore 049323

Dress code:

Smart casual

SCHEDULE

PRE-EVENT ACTIVITIES (APRIL 23, 2024) - 23/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

TIME	
17:00	17:30 - Welcome Reception

SESSIONS

APRIL 24 - DAY ONE - 24/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Breakfast and Registration

08:00 - 09:00

Opening Remarks

09:00 - 09:30

Location: Room 3102/3103

Participants

Panelist: Rosie Bernard - Senior Director, EBD Group

Panelist: Lee Chuan Teck - Chairman, Enterprise Singapore

Pharma perspectives: breaking barriers to build on opportunities in Asia Pacific

09:30 - 10:30
Plenary Sessions

Location: Room 3103/ 3104

As well as a growing hotspot for clinical trials, Asia Pacific holds the world's second and third largest pharmaceutical markets with China and Japan leading the charge. The distinguished opening keynote panel will consist of influential pharma dealmakers leading the path to development, funding, and partnerships in the burgeoning Asian market.

Participants

Moderator : Helen Chen - Global Sector Co-Head, Healthcare and Life Sciences Greater China Managing Partner, L.E.K. Consulting

Panelist: Ya-Ting Lei - Director of Business Development & Licensing, Merck Group

Panelist: Geoff Quinn - Senior Director, Pfizer

Panelist: Jenny Yang - Senior Director, Global Search & Evaluation, Novo Nordisk

Panelist: Koji Yashiro - Director at Pacific BD&L, MSD

Partnering: One-to-one meetings

09:30 - 17:00
One-to-One Meetings

Immuno-Oncology: Carina Biotech

10:30 - 10:45
Company Presentations

Location: Room 3102

Carina Biotech is an Australian immuno-oncology company developing CAR-T and other adoptive cell therapies for the treatment of solid cancers. In addition to its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer, Carina has a deep pipeline of CAR-T programs as well as platform technologies for the positioning of CAR-T cells within solid tumours, to enhance potency and induce "serial" killing that is capable of memory and a proprietary 5-day manufacturing process. The company has a pipeline of novel CAR-T programs in preclinical development for the treatment of a range of solid cancers, with the lead program targeting LGR5, a cancer stem cell marker.

In addition, the company has developed a proprietary multi-functional chemokine receptor platform to enable CAR-T cell arming, homing and access to tumours and an efficient CAR-T cell manufacturing platform to increase efficacy and persistence within tumours.

Using its proprietary chemokine receptor platform, Carina aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects.

Carina also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust "serial-killing" CAR-T cells to patients.

Participants

Presenter: Deborah Rathjen - CEO & Managing Director, Carina Biotech

Networking Coffee Break

10:30 - 11:00
Networking Opportunities

Immuno-Oncology: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

10:45 - 11:00
Company Presentations

Location; Room 3102

ImmuneOnco is a HongKong stock exchange-listed, clinical stage biotech company focused on discovering and developing immunotherapies to treat cancer.

The most advanced clinical program is timdarpacept (IMM01), an SIRPa-IgG1 Fc with ADCC/ADCP inducing activity. It has entered phase III in 2024 with the planned BLA submission in 2025 to treat higher-risk myelodysplastic syndromes (HR-MDS) and R/R classic Hodgkin lymphoma (cHL). Timdarpacept in combination with azacitidine to treat chronic myelomonocytic leukemia (CMML) was approved by FDA for Orphan Drug Designation.

Other clinical stage assets include VEGFxPD-L1, PD-L1xCD47, CD47xCD20, CD47xHER2 (Fast Track designation by FDA), ADCC-enhanced CTLA-4 mAb, CD24 mAb, CD70 mAb etc.

Participants

Presenter: Wenzhi Tian - Founder and CEO, ImmuneOnco

Deals, breakthrough innovation, and partnering for biotech's next generation

11:00 - 12:00
Plenary Sessions

Location: Room 3103/ 3104

What assets are driving investments and partnerships? With the rise of antibody drug conjugates (ADC's) in cancer drug development, what do investment and innovation look like in the Asian market in the next 10 years? Experts will share their insights on emerging areas of innovation, what deals to watch for, and how this impacts the future of development.

Participants

Moderator: David Chen - Managing Director, BFC Group

Panelist: Guy Heathers - CBO, Albatroz Therapeutics

Panelist: Shyam Masrani - Principal, Medicxi

Panelist: Damian O'Connell - CEO, Experimental Drug Development Centre

Panelist: Arthur Pappas - CEO & Managing General Partner, Pappas Capital

SESSIONS

APRIL 24 - DAY ONE - 24/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Immuno-Oncology: TRACON Pharma

11:00 - 11:15

Company Presentations

Location: Room 3102

TRACON is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer. Our lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma in a pivotal trial.

TRACON offers partners a novel solution for clinical development and commercialization of their products in the U.S. TRACON is a CRO-independent company which offers our partners improved quality, decreased timelines, greater development control and reduced cost. We have executed several deals already using this novel partnering approach and our partners include J&J, 3D Medicines, Alphamab Oncology, Eucure Biopharma and I-Mab. We have conducted more than 15 clinical trials using our CRO-independent platform, including at all Phases of development. Employing this capability we serve as a solution for developing and commercializing oncology products in the US. The key to our partnering model is the strong and lasting alignment we create through our deal designs. We strive to create alignment through cost share and risk share deals for development and profit sharing upon product approval by the FDA. In select instances TRACON will conduct the trial(s) as well as absorb all the clinical trial costs. We have the expertise to lead US commercialization as well. Our preference is to work with first-in-class, best-in-class or fast-follower oncology and other physician specialist prescribed products. Our deal structures are customized to meet the needs of each corporate partner.

Participants

Presenter: Charles Theuer - CEO, TRACON Pharma

Oncology: Invion Limited

11:15 - 11:30

Company Presentations

Location: Room 3102

Invion is a life-science company that is leading the global research and development of the Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion is developing Photosoft as a novel next generation Photodynamic Therapy (PDT). Its lead drug candidate, INV043, is a novel, patent protected photosensitizer, which in conjunction with light and oxygen, selectively kills cancer cells and promotes an immune response with the potential to attack other related cancers. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. Invion has partnered with world-leading institutions like the Peter MacCallum Cancer Centre and Hudson Institute of Medical Research. Invion will commence a Phase I/II skin cancer trial in the coming months.

Participants

Presenter: Thian Chew - Chairman and CEO, Invion Limited

Oncology: Boryung Co., Ltd.

11:30 - 11:45

Company Presentations

Location: Room: 3102

Boryung is a pharmaceutical company based in South Korea and currently has a total of 27 affiliates with a diverse business portfolio ranging from research and development of new drugs to manufacturing and sales of drug products, APIs, and consumer products. Since its foundation in 1957, Boryung has been innovating and taking on challenges to become an indispensable contributor to human health. Boryung's steady growth is evidenced by increases in both sales and operating profit(s) in 2022 - sales increased by 21% (total sales of 760.5 billion KRW) and operating profit(s) increased by 37% (total operating profit(s) of 56.6 billion KRW). As a result of continuous developments, Boryung has become the major leading company in the domestic pharmaceutical market for hypertension, diabetes, and cancer sectors. In order to leap forward as the No. 1 pharmaceutical company in South Korea and into a global innovative pharmaceutical company, Boryung continuously strives to focus on strengthening research capabilities and developing innovative medicines with our innovative drug research center. Based on the diverse R&D experiences accumulated over the past 60 years, Boryung is expanding our research and drug development capacity to NCE (New Chemical Entity) and thus, aggressively investing in anticancer drugs as a future growth catalyst. Specifically, BR101801 is a first-in-class anticancer drug that triple-inhibits PI3K delta/gamma and DNA-PK and is currently being developed by Boryung as a treatment for peripheral T-cell lymphomas (PTCL).

Participants

Presenter: Bong Seog Kim - CTO, Boryung Co., Ltd.

SESSIONS

APRIL 24 - DAY ONE - 24/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Oncology: Zymeworks

11:45 - 12:00

Company Presentations

Location: Room 3102

Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody drug conjugates (ADC) and multispecific antibody therapeutics (MSAT) across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Participants

Presenter: Lucas Donigian - VP, Business & Commercial Development, Zymeworks

Networking Lunch

12:00 - 13:30

Networking Opportunities

Asia Bio Partnering Forum Workshop Session 1: Out-Bound Deals - What is Sought after, and How to Get a Deal Done?

13:30 - 14:30

Plenary Sessions

Location: Room 3103/ 3104

Hear pharma's perspectives on outbound licensing deals, acquisitions, and collaborations, and strategies on how to get a deal done.

Participants

Moderator: Jennifer Raab - Partner, Cooley

Panelist: David Chen - Managing Director, BFC Group

Panelist: Lila Hope - Partner, Cooley

Panelist: Birgit Reitmaier - Head of BD Asia Pacific, Merck

Panelist: Matthew Sheroff - Head of New Business Development, Janssen Asia Pacific

Oncology: ZTI Biosciences

13:30 - 13:45

Company Presentations

Location: Room 3102

ZTI BIOSCIENCES specializes in the development of radiopharmaceuticals for cancer therapeutics based on the Nano-tech platform (TERACARRIER™), distinguished as the world's first and only technology.

[Latest Update]

We are excited to announce a significant breakthrough and the expansion of our pipeline at Asia Bio. In addition to our existing pipeline, ZTI has initiated the development of novel drugs incorporating antibodies as target moieties. The ZTI-201A pipeline, utilizing HER2-the most renowned and widely employed antibody in the ADC industry-targets breast cancer.

This expansion of our pipeline, made possible by leveraging TERACARRIER™, our platform technology for drug delivery systems, aims to overcome the limitations of the ADC industry. It is poised to emerge as a highly effective treatment option for patients with low HER2-expressed breast cancer.

[Pipeline]

ZTI-101 utilizes 177Lu for orphan disease (ovarian cancer), targeting IND approval this year. ZTI-102S is using 225Ac, which is Targeted Alpha Therapy (TAT) with strong therapeutic activity, overcoming the technically challenging delivery of high-energy alpha daughters through TERACARRIER™ technology. TERACARRIER™'s versatile platform extends to the new targeting agent applied pipeline, designed for solid tumor treatment using from small molecule to antibody. Our new pipeline ZTI-201A is using anti-HER2 antibody for HER2 low expressed breast cancer patient.

[Stage]

Nonclinical Stage for ZTI-101(Lu-177, Ovarian Cancer, ODD), Optimizing stage for ZTI-102S(TAT, Ac-225) and ZTI-201A (HER2, Breast Cancer).

[Patent]

The patented platform and the patented synthesizer equipment empower us to fully harness the potential of radiopharmaceuticals, marking a significant advancement in cancer treatment.

[Financial Growth]

We are currently ongoing efforts to secure \$15 million in Series B funding. We are also strategically planning an IPO in 2025.

Participants

Presenter: Jaden Hyungseok Chang - CEO, ZTI Biosciences

SESSIONS

APRIL 24 - DAY ONE - 24/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Drug Delivery: Westlake Genetech

13:45 - 14:00

Company Presentations

Location: Room 3102

We focus on AI-accelerated drug design and discovery for safe, effective, and accessible gene therapies.

Four innovative AI-accelerated platforms have been established, including Aldit-CAPSID for capsid evolution, Aldit-EDITOR for enzyme discovery, Aldit-CRISPR for effective editing, and AIDIT-TARGET for target discovery. Besides, a novel ex vivo CRISPR therapy for untreatable primary immune deficiency has been ready for investigator-initiated trials in China.

The company's leading platform, Aldit-CAPSID, has developed superior liver-sparing AAV targeting various therapeutically relevant organs, such as muscles, CNS, heart, and immune cells. In NHP, an AI-generated AAV variant, MUS001, has demonstrated more than one magnitude higher transduction rates in pan-muscles and one magnitude lower in the liver by intravenous injection and has potential superiority to current DMD gene therapies.

Participants

Presenter: Lijia Ma - Scientific Founder, Westlake Genetech

Drug Discovery & Development: Halia Therapeutics

14:00 - 14:15

Company Presentations

Location: Room 3102

At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.

Founded in 2017, our incredible team of scientists has worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.

Participants

Presenter: David Bearss - CEO, Halia Therapeutics

Drug Discovery & Development: Biolexis Therapeutics

14:15 - 14:30

Company Presentations

Location: Room 3102

Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern AI-enabled drug discovery process.

Participants

Presenter: Kyle Medley - Director Business Development, Biolexis Therapeutics

Asia Bio Partnering Forum Workshop Session 2: Fundraising and capital markets trends for Asia life sciences companies

14:30 - 15:30

Plenary Sessions

Location: Room 3103/ 3104

Discussing key trends and considerations for dealing with investors and securing financing for life sciences companies, from private financing to capital markets transactions.

Participants

Moderator: Yiming Liu - Partner, Cooley

Panelist: Joe Gao - CFO, Singleron Biotechnologies

Panelist: Xiao Le - CFO, MegaRobo

Panelist: Fong Ming Koh - Principal, LYFE Capital

Panelist: Wenzhi Tian - Founder and CEO, ImmuneOnco

Panelist: Michael Yu - Partner, Cooley

Drug Discovery & Development: NetTargets, Inc.

14:30 - 14:45

Company Presentations

Location: Room 3102

As productivity in the pharmaceutical industry has declined, pharma are struggling to find the best way to escape from the drug development recession. One emerging solution for that is AI-based drug development, but the advantages from AI is not much more than time reduction.

NetTargets has its own unique solution, AI-enhanced Systems Biology, based on over 20 years of accumulated technology from KAIST. We have built a drug development platform. The platforms facilitate simulating life systems using big data such as mutation on genes and proteins, etc. The solution enables dynamic analysis and an exact understanding of biological phenomena, and leads to faster drug development.

We have collaborated with pharmaceutical and biotech companies to conduct target discovery and mechanism analysis for various diseases such as cancer, immuno-therapy, synthetic lethality, rare diseases, cardiovascular diseases, etc.

NetTargets has two kinds of business models. The first business model is CRS (contract research service or collaboration) for target identification, drug repurposing, mechanism analysis, etc. The second business model is drug pipeline collaboration (co-development, L/O, etc.).

We are looking for synergetic partners to cooperate and discover novel drug targets. We are open to all bio/pharmaceutical companies as well as all institutes that are interested in/willing to adopt AI-enhanced systems biology for the drug development process. NetTargets has two kinds of business models. The first business model is CRS (contract research service or collaboration) for target identification, drug repurposing, mechanism analysis, etc. The second business model is drug pipeline collaboration (co-development, L/O, etc.).

NetTargets has collaborated with pharmaceutical and biotech companies to conduct target discovery and mechanism analysis for various diseases such as cancer, immuno-therapy, synthetic lethality, rare diseases, cardiovascular diseases, etc.

Participants

Presenter: Jongho Baek - COO, NetTargets, Inc.

SESSIONS

APRIL 24 - DAY ONE - 24/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Large Pharma: ATLATL Scientific

14:45 - 15:00

Company Presentations

Location: Room 3102

The ATLATL Center for Innovation & Research is a global innovation research and development center located in the heart of multiple prestigious science parks in China, creating a new life sciences ecosystem by partnering with entrepreneurs, investors, pharmaceutical companies, and service companies. This ecosystem attracts top research projects and talent from around the world, promoting the research and development of drugs that benefit healthcare around the world.

Participants

Presenter: Raymond Ng - Senior Director, Strategic Innovation & Business Development, ATLATL Scientific

Biotech: NRW.Global Business

15:00 - 15:15

Company Presentations

Location: Room 3102

BIO.NRW is the official network for biotechnology and life sciences in the German Federal State of North Rhine-Westphalia (NRW). We actively promote the continuous development of the biotech sector in NRW, which is already one of the leading ones in Germany. BIO.NRW initiates and supports collaborations between all players in the fields of pharmaceutical biotechnology (BIO.NRW.red), industrial biotech and the bioeconomy (BIO.NRW.eco) - along the value chains, in order to transform ideas and scientific findings more effectively into forward-looking processes and marketable products. We support start-ups and SMEs through various measures, act as a point of contact for scientists, business leaders and investors and thus strengthen technology-transfer and growth. Our activities aim to create an effective network for companies and scientists, and to provide an event platform for life science topics.

Participants

Presenter: Yazmin Stoffer - Head of Business Unit ASEAN, NRW.Global Business

Immunology: MetrioPharm AG

15:15 - 15:30

Company Presentations

Location: Room 3102

MetrioPharm AG is a Swiss biotech company developing first-in-class auto-regulated immune modulators targeting the pathologically dysregulated mitochondrial metabolism in macrophages. MetrioPharm's platform of oral small molecules has demonstrated preclinical & clinical efficacy (three Phase II studies) in several inflammatory and infectious diseases with an excellent safety profile. As a monotherapy, MetrioPharm's lead candidate MP1032 produces therapeutic effects similar to corticosteroids (cortisone-based therapeutics), but without serious side effects.

MP1032 has demonstrated synergistic/supra-additive effects in combination with an ultra-low dose (10% of the normal dose) of corticosteroids, demonstrating the potential to create a new class of "super corticosteroids" that are more effective and have no serious side effects. For more than 60 years, there have been no major advances in achieving such corticosteroid-sparing therapy and thereby reducing corticosteroid-specific side effects.

In addition, MP1032 has demonstrated broad host-directed antiviral activity in preclinical studies against 6 tested COVID-19 variants and multiple influenza virus variants, as well as antibacterial activity against multiple bacterial strains.

The Company is headquartered in Zurich and has a subsidiary for R&D activities in Berlin.

Participants

Presenter: Thomas Christely - CEO, MetrioPharm AG

Antibodies: EarwynBio

15:30 - 15:45

Company Presentations

Location: Room 3102

EarywunBio is a bio-company that has successfully established a platform named "SLiME" able both to screen and to produce modified hagfish antibodies (Cccombody) by gram-positive bacteria. The antibodies are useful for the diagnosis of LFA, passive immune antibodies for honey bees and shrimp, and treatment for animal and human diseases.

Participants

Presenter: Mr. Tae Sunfg Jung - CEO & Professor, EarwynBio

Networking Coffee Break

15:30 - 16:00

Networking Opportunities

Ophthalmology: Kiora Pharmaceuticals

15:45 - 16:00

Company Presentations

Location: Room 3102

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Participants

Presenter: Brian Strem - CEO, Kiora Pharmaceuticals

Innovation and Collaboration in Asia: Current status and future directions

16:00 - 17:00

Plenary Sessions

Location: Room 3103/ 3104

Participants

Moderator: Brian Yang - Managing Editor, Citeline

Panelist: Anand Gautam - Founder, G2OME CONSULTING PTY LTD

SESSIONS

APRIL 24 - DAY ONE - 24/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Infectious Diseases: TaiMed Biologics

16:00 - 16:15

Company Presentations

Location: Room 3102

TaiMed Biologics is a leading biopharmaceutical developer and manufacturer based in Taiwan. Founded in 2007, we have extensive experience in the development and manufacturing of monoclonal antibodies (mAb). Our most notable achievement is the successful development and commercialization of Trogarzo, the world's first and only mAb for HIV therapy, which is currently available in the US. We are actively seeking marketing partners for regions outside of the US. Continuing with our success, TaiMed is currently developing best-in-class long-acting mAbs for HIV therapy, which is in Phase 2 clinical study.

We also specialize in providing contract development and manufacturing services for monoclonal antibodies (mAb). Our extensive experience in mAb development and manufacturing allows us to assist biopharmaceutical companies in bringing crucial mAb molecules from development to clinical trials and ultimately to market. We take pride in offering our services to help others move forward with important monoclonal antibodies.

Participants

Presenter: Jimmy Chang - CEO, TaiMed Biologics

Infectious Diseases: Island Pharmaceuticals Ltd

16:15 - 16:30

Company Presentations

Location: Room 3102

Island Pharmaceuticals (ASX:ILA) is a clinical stage antiviral drug development company focused on rational repurposing strategies for rapid development of prophylactic or therapeutic molecules targeting emerging viral threats. Island is developing a lead molecule, ISLA-101, for the prevention and/or treatment of dengue infections. ISLA-101 has been studied in 40+ clinical trials, primarily in cancer, but has yet to be approved for any indication. Relying on the vast publicly available clinical and pre-clinical data, as well as data from partners, Island has recently completed dosing in a Phase 1 dose escalation study.

This will be followed by a Phase 2a clinical trial, which is expected to begin enrolling in 2024.

The robust pre-clinical data package includes animal data from two different labs demonstrating that ISLA-101 protects against dengue infection. ISLA-101 also protects against Zika infection in an animal model.

The Phase 2a trial will be a challenge trial in healthy individuals and will be conducted at SUNY Upstate in Syracuse, NY. In this study we plan initially to dose subjects with ISLA-101 prior to infection in a prophylactic study. The study is anticipated to begin Q3 2024.

Participants

Presenter: David Foster - CEO, Island Pharmaceuticals Ltd

CNS/Neurology: Moleac

16:30 - 16:45

Company Presentations

Location: Room 3102

Moleac is an emerging market neurology platform, strategically located in Singapore to develop and commercialize innovative medicines and solutions to meet CNS therapeutic needs. Moleac has commercial presence in more than 30 countries and holds strategic know-how and networks for regulatory, research, marketing and commercialization of first-in-class, innovative neurological products.

Participants

Presenter: David Picard - CEO, Moleac

Cardiovascular: ThromBio

16:45 - 17:00

Company Presentations

Location: Room 3102

ThromBio (and associated entities) is a clinical stage drug discovery company established to commercialise the scientific discoveries of Founder, Scientific and Medical Officer, Prof. Shaun Jackson (Heart Research Institute), and his collaborator, Prof. Richard Payne (University of Sydney).

Both the Jackson and Payne laboratories are international recognised authorities in the identification and in-vivo characterisation of novel therapeutic products for treatment of thrombotic disorders, with an initial focus on the treatment of Acute Ischemic Stroke (AIS). These discoveries have emanated from their pioneering breakthroughs on the key pathological mechanisms driving arterial thrombus formation, as well as through the discovery of new classes of nature-inspired anticoagulant agents. These exciting antithrombotic drugs have novel mechanisms of action, act synergistically together, and have a wide therapeutic window.

ThromBio has significant experience in progressing small molecule drug candidates from discovery to human trials, with its 'clinical lead', the novel antiplatelet inhibitor TBO-309. TBO-309 has an unprecedented safety profile, and the potential to transform the standard of care for AIS whilst dramatically expanding the potential of acute stroke treatment.

Professor Payne's laboratory has discovered naturally occurring anticoagulants derived from blood-feeding organisms (the saliva of the Australian 'bush tick'), leading to the patented discovery of new anticoagulant agents from two distinct peptide families that cause minimal bleeding, whilst being highly efficacious, therefore serving as potentially highly attractive candidates for use in acute stroke therapy. Stars

This portfolio of novel anticoagulants potentially allows for a valuable extension of acute treatment windows, and a whole new generation of conjunctive therapies, dramatically improving patient outcomes and health economics worldwide.

Participants

Presenter: Peter Bush - CEO, ThromBio

Exhibition Hall Networking Reception

17:00 - 18:30

SCHEDULE

APRIL 24 - DAY ONE - 24/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

TIME	PLENARY SESSIONS	COMPANY PRESENTATIONS	NETWORKING OPPORTUNITIES	ONE-TO-ONE MEETINGS
08:00	08:00 - Breakfast and Registration	08:00 - Breakfast and Registration	08:00 - Breakfast and Registration	08:00 - Breakfast and Registration
09:00	09:30 - Pharma perspectives: breaking barriers to build on opportunities in Asia Pacific 09:00 - Opening Remarks	09:00 - Opening Remarks	09:00 - Opening Remarks	09:30 - Partnering: One-to-one meetings 09:00 - Opening Remarks
10:00		10:30 - Immuno-Oncology: Carina Biotech 10:45 - Immuno-Oncology: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	10:30 - Networking Coffee Break	
11:00	11:00 - Deals, breakthrough innovation, and partnering for biotech's next generation	11:00 - Immuno-Oncology: TRACON Pharma 11:15 - Oncology: Invion Limited 11:30 - Oncology: Boryung Co., Ltd. 11:45 - Oncology: Zymeworks		
12:00			12:00 - Networking Lunch	
13:00	13:30 - Asia Bio Partnering Forum Workshop Session 1: Out-Bound Deals - What is Sought after, and How to Get a Deal Done?	13:30 - Oncology: ZTI Biosciences 13:45 - Drug Delivery: Westlake Genetech		
14:00	14:30 - Asia Bio Partnering Forum Workshop Session 2: Fundraising and capital markets trends for Asia life sciences companies	14:00 - Drug Discovery & Development: Halia Therapeutics 14:15 - Drug Discovery & Development: Biolexis Therapeutics 14:30 - Drug Discovery & Development: NetTargets, Inc. 14:45 - Large Pharma: ATLATL Scientific		

SCHEDULE

APRIL 24 - DAY ONE - 24/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

TIME	PLENARY SESSIONS	COMPANY PRESENTATIONS	NETWORKING OPPORTUNITIES	ONE-TO-ONE MEETINGS
15:00		15:00 - Biotech: NRW.Global Business 15:15 - Immunology: MetrioPharm AG 15:30 - Antibodies: EarwynBio 15:45 - Ophthalmology: Kiora Pharmaceuticals	15:30 - Networking Coffee Break	
16:00	16:00 - Innovation and Collaboration in Asia: Current status and future directions	16:00 - Infectious Diseases: TaiMed Biologics 16:15 - Infectious Diseases: Island Pharmaceu- ticals Ltd 16:30 - CNS/Neurology: Moleac 16:45 - Cardiovascular: ThromBio		
17:00	17:00 - Exhibition Hall Networking Reception	17:00 - Exhibition Hall Networking Reception	17:00 - Exhibition Hall Networking Reception	17:00 - Exhibition Hall Networking Reception

SESSIONS

APRIL 25 - DAY TWO - 25/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Breakfast and registration

08:00 - 09:00

Startup spotlight pitch competition

09:00 - 10:30
Startup Spotlight

Location: Room 3103/ 3104

New for Asia Bio Partnering Forum, we are excited to launch the startup spotlight pitch competition. This high-energy session will feature some of the most innovative startup biotech companies entering the market today. The live pitch competition will give a group of hand selected startups the opportunity to pitch in front of the Asia Bio Partnering Forum judges and audience, with the winner announced at the end of the session.

Participating Companies:

Ananda Immunotherapies

Biorevert Inc

Fermelanta, Inc.

Elix, Inc.

Medicovestor, Inc.

VRG Therapeutics

Participants

Judge: Tam C. Nguyen - Deputy Director of Research IC, Horizon 3 Healthcare, St Vincent's Hospital Melbourne

Judge: Ryan Wang - Head of Lilly Innovation Center, Eli Lilly

Judge: Min Wu - CBO, SciClone Pharmaceuticals

Presenter: Adrian Lim - CEO, Ananda Immunotherapies

Presenter: Mr. Sea Choi - Co-Founder and Chief Global Strategist, Biorevert Inc

Presenter: Mr. Shogo Fukizaki - Co-Founder & CEO, Fermelanta, Inc.

Presenter: Shinya Yuki - CEO & Co-Founder, Elix, Inc.

Presenter: Lin Ong - CBO, Medicovestor, Inc.

Presenter: Mr. Zalán Péterfi - CEO & Co-Founder, VRG Therapeutics

Partnering: One-to-one meetings

09:00 - 17:00
One-to-One Meetings

Pain Management: Adepthera LLC

10:30 - 10:45
Company Presentations

Location: Room 3102

Adepthera is a preclinical-stage company dedicated to advancing long-acting peptide therapeutics through its leading scientific work on self-assembling slow-release peptides for GPCR targets. Adepthera's vision is to improve patients' lives with highly innovative therapies. Adepthera is dedicated to filling this gap by developing precise and efficient treatments using unique self-assembled peptide analogs. Innovative peptide solutions are at the core of what we are developing at Adepthera. Our innovative approach integrates foundational science with innovative analogs to deliver new classes of peptide therapeutics for patients who suffer chronic pain, chronic wounds, or endothelial dysfunction. We have developed the first CGRP antagonist suitable for intra-articular delivery to alleviate joint pain and the first CLR/RAMP receptor agonist ideal for augmenting localized healing of chronic wounds. These self-assembled therapeutic candidates are currently in the IND-enabling stage of development. They are indicated for the prevention/mitigation of osteoarthritis pain and chronic migraine headaches in patients who are resistant to available therapies or for accelerating the healing of diabetic ulcers and pressure ulcers. In addition, select self-assembling candidates are indicated for the treatment of life-threatening cardiovascular diseases (e.g., stroke, preeclampsia, and resistant hypertension) resulting from endothelial dysfunction and the loss of vascular integrity. With these novel assets, our team of experienced drug developers is working to launch a new world of innovative peptidomimetic drugs.

Participants

Presenter: Sheauyu Teddy Hsu - CEO, Adepthera LLC

Networking Coffee Break

10:30 - 11:00
Networking Opportunities

Technologies & Tools: Cubic K Co., Ltd.

10:45 - 11:00
Company Presentations

Location: Room 3102

Cubic-K is a leading innovator in the field of real-time monitoring technology for substances within reactors. Specializing in advanced sensing solutions, the company offers cutting-edge tools for continuously monitoring and analyzing materials within reactors during various chemical processes.

[Key Features]

Raman Signal Technology: Cubic-K employs sophisticated Raman signal-based monitoring systems, offering a unique and precise method for analyzing chemical compositions in real-time.

Innovative Sensing Solutions: The company's technology utilizes innovative sensing solutions, ensuring accuracy and reliability in monitoring reactor substances, even in dynamic and challenging environments.

Live Data Analytics: Through advanced live data analytics, Cubic-K translates complex Raman signals into actionable insights, facilitating prompt decision-making and optimal process adjustments.

Versatile Applications: The company's solutions cater to a broad spectrum of reactors and chemical processes, providing versatility and adaptability to diverse industrial requirements.

[Benefits]

Enhances safety protocols with immediate, real-time insights into chemical composition variations. Optimizes reactor efficiency by continuously monitoring and adapting to changing process conditions. Empowers operators with data-driven decision-making, resulting in improved overall process control.

As a trailblazer in Raman signal-based monitoring, Cubic-K stands as a leader in providing innovative solutions for real-time substance monitoring within reactors, contributing significantly to the advancement and reliability of industrial processes.

Participants

Presenter: Dongchoul Kim - CEO, Cubic K Co., Ltd.

SESSIONS

APRIL 25 - DAY TWO - 25/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Cross border investment: from local discovery to global innovation

11:00 - 12:00

Plenary Sessions

Location: Room 3103/ 3104

This session will showcase the benefits, opportunities, and financing available in the APAC region and the most effective way of leading their respective business deals. Leading investors will share their insights on their success in investing across borders, where the focus is shifting in the next decade, the rising appeal of business in Asia, and the global impact.

Participants

Moderator: Min Wu - CBO, SciClone Pharmaceuticals

Panelist: Vince Deng - Partner, Med-Fine Capital

Panelist: Navjeevan Khosla - Partner, Novo Holdings

Panelist: Yuwen Liu - Founding Partner, Bohe Angel Fund

Panelist: Jing Xu - Investment Principal, LYFE Capital

Autoimmune/Inflammation: Noxopharm

11:00 - 11:15

Company Presentations

Location; Room 3102

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilizes specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms - Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

The Sofra platform is focused on developing a novel class of immunomodulators capable of improving mRNA vaccines and mRNA therapeutics, as well as treating autoimmune diseases. This platform is based upon short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These oligonucleotides provide a novel treatment approach, acting on specific cells to modulate inflammation at its source.

Chroma is a small molecule technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. Its leading preclinical drug candidate CRO-67 is showing promising signals for the treatment of pancreatic cancer.

Noxopharm also has a major shareholding in US biotech company Nyrada Inc (ASX:NYR), which focuses on drug development for cardiovascular and neurological diseases.

The lead assets that have been developed to date from the Chroma (oncology) and Sofra (inflammation) platforms act in unique ways, and Noxopharm believes this distinctiveness represents a compelling point of difference for further development.

Noxopharm owns the intellectual property for the assets in both platforms, and is currently seeking partnering and investment opportunities for its technologies.

Participants

Presenter: Gisela Mautner - CEO & Managing Director, Noxopharm

Cell & Gene Therapies: Accelerated Biosciences Corp.

11:15 - 11:30

Company Presentations

Location: Room 3102

Accelerated Biosciences is a regenerative medicine company with freedom-to-operate for the human Trophoblast Stem Cell (hTSC) platform with 49 patents granted. We are providing GMP cells with a complete regulatory package to help cell and gene therapy developers accelerate their product time to market by 3 to 5 years with a potential \$10M in savings. We have effectively de-risked the starting cell source decision for the regenerative medicine industry. We are available for partnering and licensing opportunities.

Participants

Presenter: Yuta Lee - Accelerated Biosciences Corp., Accelerated Biosciences Corp.

SESSIONS

APRIL 25 - DAY TWO - 25/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Ophthalmology: Curacle

11:30 - 11:45

Company Presentations

Location: Room 3102

Curacle is a Korean R&D-focused biopharmaceutical company founded in 2016. Our core research area is vascular diseases, specifically, we are developing treatments for vascular endothelial dysfunctions based on our proprietary discovery platform technology called Solvadys.

We are currently conducting clinical trials in the fields of ophthalmology and diabetes, and we have three other projects in preclinical stages for IBD, Oncology Combination, Diabetic nephropathy and more pipelines in the discovery stage in the oncology. The chairman of the clinical advisory committee is professor In-kyu Lee, a specialist in Diabetes and Metabolic disease, and the cofounder of Curacle.

Many experts are actively participating as our clinical advisors, and they have provided immense support for clinical trials of our multiple pipelines for the past 7 years.

In addition, our unique platform Solvadys, and CU06 which is developed based on Solvadys, have been successfully introduced as a novel treatment in various international academic journals and conferences. CU06 is under phase 2 in the US, and it is expected to be completed early this year and we are planning to submit IND in the 3rd quarter of 2024.

We closed a licensing agreement for CU 06 for development and commercialization in October in 2021. From the terms of the agreement, Curacle is eligible to receive up to 2 billion dollars in total payment in milestones and royalties. As the deal covers global regions except for Asia, we are still looking for partners for the Asian region including Great China and Japan. From phase 2 of CU06, we will expand indications to wet-amd, Diabetic retinopathy, and Inflammatory bowel disease. 5. Founder and Chairman Kwon is a professor in Biochemistry at Yonsei University and has researched vascular disease for over three decades and is considered a top expert internationally in the field of vascular disease. Many Thanks.

Participants

Presenter: Jeonghan Kim - Senior Director, Curacle

Immuno-Oncology: Biomissile Pharmaceuticals

11:45 - 12:00

Company Presentations

Location: Room 3102

Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDAB) and multi-specific antibody (UDAB-M) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDAB) and multi-specific antibody (UDAB-M), as well as the largest libraries of phage, yeast and mammalian cell display platforms.

BM230 (IND), a lead and proof of concept for the NK engager platform, showing excellent potency, selectivity, and safety profiles against Her2-expression tumors, including Her2-low and ADC-resistant; superior combo effect with NK cells, PD-1 and small molecule anticancer drugs. Platform technology can be readily adapted to other TAA and next-gen NK engager (NK 2.0) to target TAA-extremely low tumors.

BM012 (Phase 1b), a novel neutralizing antibody targeting HBV surface antigen (HBsAg), showing stronger efficacy than VIR3434 to decrease HBsAg and synergistic effect with siRNA (HT101) for the functional cure of HBV.

BM219 (Phase 2), a potent broad-neutralizing, inhaled, anti-COVID-19 UDAB-M molecule, possessing unique epitopes and excellent anti-viral activity against WT and all variants, including XBB and BA.2.86.

Participants

Presenter: Chao Tu - Co-founder, President & CEO, Biomissile Pharmaceuticals

Networking Lunch

12:00 - 13:30

Networking Opportunities

Oncology: Genome Opinion

13:00 - 13:15

Company Presentations

Location: Room 3102

Genome Opinion is at the forefront of precision medicine development targeting diseases driven by Clonal Hematopoiesis (CH). Utilizing our proprietary GENO-VERSE database, we employ a strategic methodology to enhance our research and development efforts.

Our methodology encompasses: Identifying specific patient demographics for targeted therapeutic interventions. Discovering or acquiring tailored treatments for these groups. Expediting the clinical trial process via early local POC studies.

Participants

Presenter: Mr. Myung Sea Lee - CEO, Genome Opinion

Academic Innovators: National Chung Hsing University

13:15 - 13:25

Company Presentations

Location: Room 3102

We are drug discover lab in Taiwan. We designed and synthesized the potent small molecules against cancers.

Participants

Presenter: Mr. Tai-Lin Chen - Assistant Professor, National Chung Hsing University

Biotech IPO landscape in Asian markets: latest trends, predictions, and emerging ways to raise funds

13:30 - 14:30

Plenary Sessions

Location: Room 3103/ 3104

So far 2024 has shown a promising start for IPOs, but is it sustainable? This session will cover opportunities and obstacles of recent biotech IPOs, reversing the previous downward trend, new and emerging ways to raise funds, what strategies can be implemented long-term, and how these pivots will affect product development.

Participants

Moderator: Yiming Liu - Partner, Cooley

Panelist: Ghee Chuan Lai - Associate, Qiming Venture Partners

Panelist: Vishal Doshi - Chairman of the Board, AUM Biosciences

Panelist: James Huang - Founder and Managing Partner, Panacea Venture

SESSIONS

APRIL 25 - DAY TWO - 25/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

Global perspectives: international collaboration to grow biopharma ecosystems

14:30 - 15:30

Plenary Sessions

Location: Room 3103/ 3104

Building a competitive landscape and create a booming biopharma ecosystem requires support across borders. Global leaders in life sciences will share their experience with business, investment, and regulations while working in Asia, and how they have been able to meet or surpass expectations.

Participants

Moderator: Brian Yang - Managing Editor, Citeline

Panelist: Taejoon Chin - CEO, C Cube Lab

Panelist: Charles Stacey - President and CEO, Cerecin

Panelist: Nils Schrader - Managing Director, BIO.NRW

Panelist: PC Zhu - Founder and CEO, ATLATL

Networking Coffee Break

15:30 - 16:00

Networking Opportunities

AI-aided drug discovery: taking action, gaining momentum, and latest developments

16:00 - 17:00

Plenary Sessions

Location: Room 3103/ 3104

Hear from the latest AI innovators and supporters as they share ever-expanding capabilities and influence in AI-aided drug discovery and development, and the industry trends that will help facilitate the path forward.

Participants

Moderator: Tam C. Nguyen - Deputy Director of Research IC, Horizon 3 Healthcare, St Vincent's Hospital Melbourne

Panelist: Anand Gautam - Founder, G2OME CONSULTING PTY LTD

Panelist: Frank Grams - CCO, Partex NV

Panelist: Yam Guan - Director, Oracle Health

Panelist: Jimmy Lin - General Manager, Insilico Medicine Taiwan

SCHEDULE

APRIL 25 - DAY TWO - 25/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

TIME	PLENARY SESSIONS	STARTUP SPOTLIGHT	COMPANY PRESENTATIONS	NETWORKING OPPORTUNITIES	ONE-TO-ONE MEETINGS
08:00	08:00 - Breakfast and registration	08:00 - Breakfast and registration	08:00 - Breakfast and registration	08:00 - Breakfast and registration	08:00 - Breakfast and registration
09:00		09:00 - Startup spotlight pitch competition			09:00 - Partnering: One-to-one meetings
10:00			10:30 - Pain Management: Adeptera LLC 10:45 - Technologies & Tools: Cubic K Co., Ltd.	10:30 - Networking Coffee Break	
11:00	11:00 - Cross border investment: from local discovery to global innovation		11:00 - Autoimmune/Inflammation: Noxopharm 11:15 - Cell & Gene Therapies: Accelerated Biosciences Corp. 11:30 - Ophthalmology: Curacle 11:45 - Immuno-Oncology: Biomissile Pharmaceuticals		
12:00				12:00 - Networking Lunch	
13:00	13:30 - Biotech IPO landscape in Asian markets: latest trends, predictions, and emerging ways to raise funds		13:00 - Oncology: Genome Opinion 13:15 - Academic Innovators: National Chung Hsing University		
14:00	14:30 - Global perspectives: international collaboration to grow biopharma ecosystems				
15:00				15:30 - Networking Coffee Break	

SCHEDULE

APRIL 25 - DAY TWO - 25/04/2024

Asia Bio Partnering Forum

Marina Bay Sands Convention Center

April 24–25, 2024 | Singapore

April 29–30, 2024 | Virtual

TIME	PLENARY SESSIONS	STARTUP SPOTLIGHT	COMPANY PRESENTATIONS	NETWORKING OPPORTUNITIES	ONE-TO-ONE MEETINGS
16:00	16:00 - AI-aided drug discovery: taking action, gaining momentum, and latest developments				